

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board of directors (the “**Director(s)**”) of TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “**Board**”) is pleased to announce that the Board proposed Dr. Zhu Xiangyang (朱向陽) (“**Dr. Zhu**”) to be appointed as a non-executive Director, subject to the approval by the shareholders of the Company (the “**Shareholders**”) at the forthcoming annual general meeting of the Company to be held on June 26, 2025 (the “**AGM**”) by way of an ordinary resolution and will take effect, if approved, from the conclusion of the AGM. The biographical details of Dr. Zhu are set out as below:

Dr. Zhu, aged 64, has over 20 years of experience in the biopharmaceutical industry. Dr. Zhu currently serves as a consultant to the Company. From May 1997 to May 2000, he conducted postdoctoral research at the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. From June 2000 to December 2005, he served successively as the senior scientist and laboratory director at Metamorphix. From January 2006 to August 2012, he served successively as the Head of Lead Expression in Biotherapeutics and the Principal Scientist at Boehringer Ingelheim. From August 2012 to March 2014, he served as the Head of Biopharm Process Development and TechTransfer at Boehringer Ingelheim in Shanghai, China. Since April 2014, he has served as a director and the general manager of Shanghai Huaota Biopharmaceutical Co., Ltd., an integrated R&D platform for new biological drugs. Since December 2020, he has served as a director of Zhejiang Huahai Biopharmaceutical Co., Ltd., a manufacturer of macromolecular pharmaceuticals.

Dr. Zhu obtained a bachelor degree in medicine from Jiangxi Medical College (currently known as Jiangxi Medical College of Nanchang University) in October 1983. He obtained a master degree in medicine from Peking Union Medical College in October 1988, and a Ph.D. degree in immunology from University of Illinois in May 1997.

The Company will enter a service contract with him subject to the approval of his appointment to the second session of the Board by the Shareholders at the AGM. The term shall commence from the date of approval by the Shareholders at the AGM and end on the expiration of the term of office of the second session of the Board. Dr. Zhu is not proposed to receive any fixed remuneration for serving as a non-executive Director, he will continue to receive remuneration of approximately RMB100,000 per annum for consultancy services provided to the Company.

Save as disclosed above, Dr. Zhu confirmed that (i) he did not hold any position within the Group or any directorship of other public companies in the last three years; (ii) he does not have any relationship with any Director, supervisor, senior management, substantial or controlling shareholder (the “**Shareholder(s)**”) of the Company; and (iii) he does not have any interest in the shares of the Company within the meaning of Part XV of the SFO (Cap. 571 of Laws of Hong Kong). There is no other information which is discloseable nor is Dr. Zhu involved in any of the matters required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning Dr. Zhu that need to be brought to the attention of the Shareholders.

A circular containing, among others, details in respect of the proposed appointment of Dr. Zhu and other matters outlined in the announcement of the Company dated March 27, 2025, together with the notice of the annual general meeting and the related proxy form, will be sent to the Shareholders in the manner as they elect to receive corporate communications and published on the websites of the Stock Exchange and the Company in due course.

By Order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Dr. WU Yusheng

Chairman, Executive Director and Chief Executive Officer

Hong Kong, May 16, 2025

As at the date of this announcement, the Board comprises Dr. WU Yusheng and Dr. JIANG Mingyu as executive Directors, Dr. LI Jun, Dr. GU Eric Hong, Dr. MENG Xiaoying and Mr. HE Chao as non-executive Directors, and Mr. ZHANG Senquan, Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua as independent non-executive Directors.